Attenuated vaccines are a type of vaccine that involves using weakened forms of live pathogens to stimulate an immune response without causing the disease. These vaccines are created by modifying the pathogen in a way that it loses its virulence or disease-causing ability while retaining its immunogenicity. The weakened pathogen in the vaccine can still replicate within the body, leading to a robust and long-lasting immune response. Common examples of attenuated vaccines include the measles, mumps, and rubella (MMR) vaccine, the oral polio vaccine (OPV), and the yellow fever vaccine. Attenuated vaccines often provide strong and durable immunity with just one or a few doses. While effective, attenuated vaccines may not be suitable for individuals with weakened immune systems, as the weakened pathogen could pose a risk. Additionally, careful handling and storage are crucial to maintaining the vaccine's viability. Despite these considerations, attenuated vaccines have played a pivotal role in preventing a range of infectious diseases, contributing significantly to global public health efforts.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States